These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 18228186)

  • 1. Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy.
    Duan D
    Curr Opin Mol Ther; 2008 Feb; 10(1):86-94. PubMed ID: 18228186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of trans-splicing adeno-associated viral vectors for Duchenne muscular dystrophy gene therapy.
    Lai Y; Li D; Yue Y; Duan D
    Methods Mol Biol; 2008; 433():259-75. PubMed ID: 18679629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future of Duchenne muscular dystrophy gene therapy: shrinking the dystrophin gene.
    Roberts M; Dickson G
    Curr Opin Mol Ther; 2002 Aug; 4(4):343-8. PubMed ID: 12222872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic strategies for Duchenne and Becker dystrophies.
    Voisin V; de la Porte S
    Int Rev Cytol; 2004; 240():1-30. PubMed ID: 15548414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy progress and prospects: Duchenne muscular dystrophy.
    Foster K; Foster H; Dickson JG
    Gene Ther; 2006 Dec; 13(24):1677-85. PubMed ID: 17066097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene therapy for duchenne muscular dystrophy: expectations and challenges.
    Rodino-Klapac LR; Chicoine LG; Kaspar BK; Mendell JR
    Arch Neurol; 2007 Sep; 64(9):1236-41. PubMed ID: 17846262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Full-length dystrophin gene transfer to the mdx mouse in utero.
    Reay DP; Bilbao R; Koppanati BM; Cai L; O'Day TL; Jiang Z; Zheng H; Watchko JF; Clemens PR
    Gene Ther; 2008 Apr; 15(7):531-6. PubMed ID: 18273052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress toward gene therapy of Duchenne muscular dystrophy.
    Hartigan-O'Connor D; Chamberlain JS
    Semin Neurol; 1999; 19(3):323-32. PubMed ID: 12194388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient and fast functional screening of microdystrophin constructs in vivo and in vitro for therapy of duchenne muscular dystrophy.
    Jørgensen LH; Larochelle N; Orlopp K; Dunant P; Dudley RW; Stucka R; Thirion C; Walter MC; Laval SH; Lochmüller H
    Hum Gene Ther; 2009 Jun; 20(6):641-50. PubMed ID: 19239382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naked plasmid DNA for the treatment of muscular dystrophy.
    Braun S
    Curr Opin Mol Ther; 2004 Oct; 6(5):499-505. PubMed ID: 15537051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).
    Athanasopoulos T; Graham IR; Foster H; Dickson G
    Gene Ther; 2004 Oct; 11 Suppl 1():S109-21. PubMed ID: 15454965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Splicing intervention for Duchenne muscular dystrophy.
    McClorey G; Fletcher S; Wilton S
    Curr Opin Pharmacol; 2005 Oct; 5(5):529-34. PubMed ID: 16085461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Construction of recombinant plasmid pVAX1-microdystrophin and preliminary study on the treatment to Duchenne muscular dystrophy].
    Xiong F; Zhang C; Zheng H; Xiao S; Yu M; Xu Y; Liu Z; Zhou C
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):624-8. PubMed ID: 19065517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part II: clinical protocol.
    Romero NB; Benveniste O; Payan C; Braun S; Squiban P; Herson S; Fardeau M
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S45-8. PubMed ID: 12206794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors.
    Blankinship MJ; Gregorevic P; Chamberlain JS
    Mol Ther; 2006 Feb; 13(2):241-9. PubMed ID: 16361117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleofection of muscle-derived stem cells and myoblasts with phiC31 integrase: stable expression of a full-length-dystrophin fusion gene by human myoblasts.
    Quenneville SP; Chapdelaine P; Rousseau J; Beaulieu J; Caron NJ; Skuk D; Mills P; Olivares EC; Calos MP; Tremblay JP
    Mol Ther; 2004 Oct; 10(4):679-87. PubMed ID: 15451452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transduction of myogenic cells by retargeted dual high-capacity hybrid viral vectors: robust dystrophin synthesis in duchenne muscular dystrophy muscle cells.
    Gonçalves MA; Holkers M; Cudré-Mauroux C; van Nierop GP; Knaän-Shanzer S; van der Velde I; Valerio D; de Vries AA
    Mol Ther; 2006 May; 13(5):976-86. PubMed ID: 16443396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy.
    Romero NB; Braun S; Benveniste O; Leturcq F; Hogrel JY; Morris GE; Barois A; Eymard B; Payan C; Ortega V; Boch AL; Lejean L; Thioudellet C; Mourot B; Escot C; Choquel A; Recan D; Kaplan JC; Dickson G; Klatzmann D; Molinier-Frenckel V; Guillet JG; Squiban P; Herson S; Fardeau M
    Hum Gene Ther; 2004 Nov; 15(11):1065-76. PubMed ID: 15610607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy: the 'pro-sense' approach to Duchenne muscular dystrophy.
    van Deutekom JC
    Eur J Hum Genet; 2005 May; 13(5):518-9. PubMed ID: 15714219
    [No Abstract]   [Full Text] [Related]  

  • 20. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part III. Ethical considerations.
    Fardeau M
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S52-4. PubMed ID: 12206796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.